Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Warter, J. M.
Right arrow Articles by Imler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warter, J. M.
Right arrow Articles by Imler, M.
NEUROLOGY 1983;33:1136
© 1983 American Academy of Neurology

The renal origin of sodium valproate-induced hyperammonemia in fasting humans

J. M. Warter, Ch. Brandt, Ch. Marescaux, L. Rumbach, G. Micheletti, G. Chabrier, J. Krieger and M. Imler

Groupe de Recherche de Physiopathnlogie Nerveuse (Drs. Warter, Marescaux, Rumbach, Micheletti, and Krieger). Clinique Neurologique, and Service de Cardiologie (Dr. Brandt), Clinique Médicale B, Hôpital Civil, Strasbourg, and the Service de Médecine Interne (Drs. Chabrier and Imler), Hôpital de Hautepierre, Strasbourg, France.

Acute administration of 1,500 mg of sodium valproate or chronic administration of 30 mg/kg/24 hours induced a more than twofold increase of renal ammoniagenesis in fasting subjects. Hyperammonemia was moderate, as normal hepatic ammonia detoxification persisted. Renal uptake of glutamine increased simultaneously.

Address correspondence and reprint requests to Dr. Marescaux, Clinique Neurologique, Hôpital Civil, 67091 Strasbourg Cédex, France.

Accepted for publication December 28, 1982.




This article has been cited by other articles:


Home page
 J Child NeurolHome page
E. Cheung, V. Wong, and C.-W. Fung
Topiramate-Valproate--Induced Hyperammonemic Encephalopathy Syndrome: Case Report
J Child Neurol, February 1, 2005; 20(2): 157 - 160.
[Abstract] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M. C. van de Poll, P. B Soeters, N. E. Deutz, K. C. Fearon, and C. H. Dejong
Renal metabolism of amino acids: its role in interorgan amino acid exchange
Am. J. Clinical Nutrition, February 1, 2004; 79(2): 185 - 197.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M Oechsner, C Steen, H J Sturenburg, and A Kohlschutter
Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency
J. Neurol. Neurosurg. Psychiatry, May 1, 1998; 64(5): 680 - 682.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
D. L. Coulter
Carnitine Deficiency in Epilepsy: Risk Factors and Treatment
J Child Neurol, November 1, 1995; 10(2_suppl): 2S32 - 2S39.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
D. L. Coulter
Review Article: Carnitine, Valproate, and Toxicity
J Child Neurol, January 1, 1991; 6(1): 7 - 14.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by AAN Enterprises, Inc.